NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 199 filers reported holding NEKTAR THERAPEUTICS in Q4 2016. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $784,073,000 | +104.6% | 206,335 | +793.5% | 0.01% | +40.0% |
| Q3 2020 | $383,129,000 | -60.9% | 23,094 | -45.4% | 0.01% | -68.8% |
| Q2 2020 | $979,343,000 | +203929.8% | 42,286 | +189.6% | 0.02% | +300.0% |
| Q4 2018 | $480,000 | -98.9% | 14,600 | -98.0% | 0.00% | -98.4% |
| Q3 2018 | $44,766,000 | +1050.5% | 734,349 | +821.4% | 0.24% | +1120.0% |
| Q2 2018 | $3,891,000 | +32.0% | 79,700 | +187.3% | 0.02% | +17.6% |
| Q1 2018 | $2,948,000 | +92.8% | 27,744 | -68.8% | 0.02% | +21.4% |
| Q3 2016 | $1,529,000 | +709.0% | 89,000 | +694.6% | 0.01% | +600.0% |
| Q4 2015 | $189,000 | -87.5% | 11,200 | -90.7% | 0.00% | -89.5% |
| Q2 2015 | $1,510,000 | +302.7% | 120,676 | +271.3% | 0.02% | +216.7% |
| Q2 2013 | $375,000 | – | 32,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |